Article
Pharmacology & Pharmacy
Jill L. Kinzer, Troy A. Halseth, Jukyung Kang, Sang Yeop Kim, Preethi Kumaran, Michael Ford, Sergei Saveliev, St John Skilton, Anna Schwendeman
Summary: FDA-approved anti-TNF alpha biopharmaceuticals have been successful in treating autoimmune diseases, but there are product-specific differences in patient outcomes, possibly due to structural and functional differences. In this study, we compared the structural and functional differences among three anti-TNF alpha mAbs (Humira (R), Remicade (R), and Simponi Aria (R)) to understand their implications on efficacy.
INTERNATIONAL JOURNAL OF PHARMACEUTICS
(2023)
Review
Medicine, General & Internal
Shinji Okabayashi, Hajime Yamazaki, Ryohei Yamamoto, Keisuke Anan, Katsuyoshi Matsuoka, Taku Kobayashi, Shinichiro Shinzaki, Yusuke Honzawa, Yuki Kataoka, Yasushi Tsujimoto, Norio Watanabe
Summary: CZP probably results in a large reduction in failure to maintain clinical remission and response at week 26 in people with CD. The evidence suggests that CZP may lead to no difference in serious adverse events compared to placebo when used as a remission maintenance treatment.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS
(2022)
Article
Dermatology
Pelin Esme, Gulsen Akoglu, Cansu Dogan Dalkiran, Ercan Caliskan
Summary: This study investigated the role of certolizumab pegol in treating severe and recalcitrant hidradenitis suppurativa (HS) patients who were unresponsive to adalimumab. The results showed that certolizumab pegol had a promising treatment effect on some patients but not all maintained response after continued therapy. Improvement in patients' dermatological life quality index and HS severity score were observed after 12 and 24 weeks of treatment.
DERMATOLOGIC THERAPY
(2022)
Article
Pharmacology & Pharmacy
Xavier Cortes, Joaquin Borras-Blasco, Laura Flor, Beatriz Antequera, Sergio Fernandez-Martinez, Jose Ramon Moles, Elvira Castera
Summary: In this case report, a 60-year-old man with ulcerative colitis refractory to azathioprine, infliximab, and adalimumab achieved successful remission with golimumab therapy. The patient showed significant improvement and sustained remission after switching to golimumab treatment, suggesting that golimumab may be an effective option for patients who do not respond to infliximab and adalimumab. Further studies are needed to confirm the efficacy of golimumab as a rescue treatment for refractory ulcerative colitis.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
(2021)
Article
Oncology
Anne Montfort, Thomas Filleron, Mathieu Virazels, Carine Dufau, Jean Milhes, Cecile Pages, Pascale Olivier, Maha Ayyoub, Muriel Mounier, Amelie Lusque, Stephanie Brayer, Jean-Pierre Delord, Nathalie Andrieu-Abadie, Thierry Levade, Celine Colacios, Bruno Segui, Nicolas Meyer
Summary: TNF blockers can help manage gastrointestinal inflammatory side effects following nivolumab and/or ipilimumab treatment in patients with advanced melanoma, and may enhance the efficacy of immune checkpoint inhibitors. The combination of certolizumab showed a high response rate in patients, warranting further investigation. Both combinations were found to be safe and showed clinical and biological activities in human patients.
CLINICAL CANCER RESEARCH
(2021)
Article
Rheumatology
Jose Luis Martin-Varillas, Lara Sanchez-Bilbao, Vanesa Calvo-Rio, Alfredo Adan, Ines Hernanz, Adela Gallego-Flores, Emma Beltran-Catalan, Sonia Castro-Oreiro, Patricia Fanlo, Alvaro Garcia Martos, Ignacio Torre, Miguel Cordero-Coma, Juan Ramon De Dios, Angel Garcia-Aparicio, Marisa Hernandez-Garfella, Amalia Sanchez-Andrade, Andrea Garcia-Valle, Olga Maiz, Roberto Miguelez, Sergio Rodriguez-Montero, Ana Urruticoechea, Raul Veroz, Arantxa Conesa, Cristina Fernandez-Carballido, Vega Jovani, Jose J. Mondejar, Olga Martinez Gonzalez, Patricia Moya Alvarado, Susana Romero-Yuste, Paula Rubio-Munoz, Eva Pena-Sainz-Pardo, Marta Garijo-Bufort, Rosalia Demetrio-Pablo, Jose L. Hernandez, Ricardo Blanco
Summary: The study evaluated the effectiveness and safety of CZP in uveitis caused by different IMIDs. The results showed that CZP was effective and safe in these patients, even in those who were refractory to previous biological drugs.
Article
Immunology
Hidefumi Kato, Megumi Hayashi, Wataru Ohashi, Takamasa Yamaguchi, Satomi Tanaka, Ayumi Kozono, Siqiang Gao, Akiko Katai, Reiko Niwa, Tomohito Matsuo, Kazuki Ishiyama, Takanori Ando, Mika Ogawa, Takayuki Nakayama
Summary: This study found that risk factors for adverse reactions associated with IVIG therapy include female sex, adult age, high dose IVIG, autoimmune disease, and neuromuscular disease. Multivariate logistic regression identified neuromuscular disease as a significant factor for adverse reactions to IVIG.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Multidisciplinary Sciences
Ian R. White, Sarah E. Kleinstein, Christophe Praet, Chris Chamberlain, Duncan McHale, Jessica M. Maia, Pingxing Xie, David B. Goldstein, Thomas J. Urban, Patrick R. Shea
Summary: This study aimed to identify genetic variants predictive of CZP response, but did not find a clear predictor of CZP response.
Article
Virology
Jing Wang, Xuedong Yin, Linlin Yu, Weiwei Cheng, Ling Wang, Bin Zhao, Zhiling Li, Xiaoping Jing
Summary: Recent evidence suggests the occurrence of delayed cutaneous hypersensitivity reactions after the application of infliximab or adalimumab in patients with COVID-19. Real-world studies comparing the events, clinical features, and prognosis of these reactions have been conducted. Disproportionality analysis and Bayesian analysis were used to identify suspected adverse events based on the Food and Drug Administration's Adverse Event Reporting Systems (FAERS). A total of 475 reports of delayed cutaneous hypersensitivity reactions were associated with infliximab or adalimumab, with infliximab showing a higher association based on reporting odds ratios and other statistical measures. The onset time and fatality rate of these reactions were compared between the two therapies.
JOURNAL OF MEDICAL VIROLOGY
(2023)
Article
Rheumatology
Jeffrey R. Curtis, Soumya D. Chakravarty, Shawn Black, Shelly Kafka, Stephen Xu, Wayne Langholff, Dennis Parenti, Andrew Greenspan, Sergio Schwartzman
Summary: The study found that the incidence of infusion reactions was significantly lower with golimumab-IV compared to infliximab in patients with rheumatoid arthritis. For biologic-naive patients, golimumab-IV showed non-inferiority in mean changes from baseline in CDAI at months 6 and 12 compared to infliximab.
RHEUMATOLOGY AND THERAPY
(2021)
Article
Dermatology
Yoshinori Umezawa, Akihiko Asahina, Shinichi Imafuku, Yayoi Tada, Shigetoshi Sano, Akimichi Morita, Shinya Sakurai, Naoki Hoshii, Nicola Tilt, Hidemi Nakagawa
Summary: The study showed that treatment with Certolizumab pegol (CZP) can improve symptoms of psoriasis in patients, and this improvement can be maintained for up to 52 weeks. The 400 mg every 2 weeks dose may provide additional clinical benefits.
DERMATOLOGY AND THERAPY
(2021)
Article
Dermatology
Shinichi Imafuku, Yayoi Tada, Yoshinori Umezawa, Shinya Sakurai, Naoki Hoshii, Hidemi Nakagawa
Summary: Certolizumab pegol (CZP) treatment demonstrated efficacy in Japanese patients with moderate to severe plaque psoriasis, with clinically meaningful improvements maintained through week 52. Numerically greater response was observed for CZP 400 mg Q2W compared to CZP 200 mg Q2W across patient subgroups in PASI 75/90 and PGA 0/1.
DERMATOLOGY AND THERAPY
(2022)
Review
Gastroenterology & Hepatology
Eun Sil Kim, Ben Kang
Summary: The selection of biologic agents for pediatric Crohn's disease should be done carefully, as currently only infliximab and adalimumab are approved for use in children. Lack of comparison trials in pediatric patients necessitates the extrapolation of adult data. From a pharmacokinetic perspective, infliximab may be more advantageous in high inflammatory burden, while adalimumab may be better in sustaining remission during maintenance phase. Factors such as clinical indications, disease behavior, efficacy, safety, immunogenicity, patient preference, and compliance should be considered when choosing anti-TNF therapy.
WORLD JOURNAL OF GASTROENTEROLOGY
(2023)
Article
Dermatology
Yukari Okubo, Yoshinori Umezawa, Shinya Sakurai, Naoki Hoshii, Hidemi Nakagawa
Summary: This study reports the efficacy and safety of certolizumab pegol (CZP) in Japanese patients with generalized pustular psoriasis (GPP) and erythrodermic psoriasis (EP). The results showed that CZP treatment improved the signs and symptoms of GPP and EP, and the improvements were maintained throughout the treatment period.
DERMATOLOGY AND THERAPY
(2022)
Article
Dermatology
Yoshinori Umezawa, Shinya Sakurai, Naoki Hoshii, Hidemi Nakagawa
Summary: This study in Japanese patients with PSO found that CZP dosed at 400 mg or 200 mg every two weeks was associated with improved signs and symptoms of PSO, as well as significant improvements in DLQI and INRS.
DERMATOLOGY AND THERAPY
(2021)
